Cargando…

Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer

BACKGROUND: PPP2R2A deletions were recently linked to a subgroup of luminal breast carcinoma (BC) that exhibits poor survival. This subgroup also exhibited amplification of a chromosome region containing the Cyclin D1 coding gene, CCND1. Therefore, we aimed to investigate whether a combination of PP...

Descripción completa

Detalles Bibliográficos
Autores principales: Beca, Francisco, Pereira, Miguel, Cameselle-Teijeiro, Jorge F, Martins, Diana, Schmitt, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409761/
https://www.ncbi.nlm.nih.gov/pubmed/25879784
http://dx.doi.org/10.1186/s12885-015-1266-1
_version_ 1782368232780333056
author Beca, Francisco
Pereira, Miguel
Cameselle-Teijeiro, Jorge F
Martins, Diana
Schmitt, Fernando
author_facet Beca, Francisco
Pereira, Miguel
Cameselle-Teijeiro, Jorge F
Martins, Diana
Schmitt, Fernando
author_sort Beca, Francisco
collection PubMed
description BACKGROUND: PPP2R2A deletions were recently linked to a subgroup of luminal breast carcinoma (BC) that exhibits poor survival. This subgroup also exhibited amplification of a chromosome region containing the Cyclin D1 coding gene, CCND1. Therefore, we aimed to investigate whether a combination of PPP2R2A (B55α) and Cyclin D1 expression statuses evaluated by immunohistochemistry (IHC) could define a subgroup of luminal BC that exhibits poor survival. METHODS: First we conducted a retrospective cohort study using sequencing data from The Cancer Genome Atlas initiative to correlate PPP2R2A copy number alteration (CNA) status with its expression level and the corresponding overall survival (OS). Next, also using a retrospective cohort study design, we evaluated the PPP2R2A (B55α) expression levels by IHC in a total of 807 BC patients from two independent cohorts (discovery cohort n = 349 and validation cohort n = 458). Cyclin D1 expression was also evaluated, and the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype was evaluated as a predictor of disease-free survival (DFS) and OS in luminal-like BC patients. RESULTS: Deletions in the PPP2R2A gene strongly correlate with lower mRNA expression and poorer OS. PPP2R2A (B55α)(-/low) carcinomas have significantly shorter DFS and OS. Furthermore, in univariate analysis, the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype is significantly associated with poorer DFS and OS. In a multivariate analysis, the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype is significantly associated with poor DFS, thus defining a group of luminal-like BC with higher risk of relapse. CONCLUSION: We demonstrate that BCs harboring PPP2R2A deletions are associated with worse OS. Moreover, this is the first study to demonstrate that the combination of altered PPP2R2A (B55α) and high Cyclin D1 expression by IHC defines a subgroup of luminal-like BC patients with a high risk of relapse and death. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1266-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4409761
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44097612015-04-26 Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer Beca, Francisco Pereira, Miguel Cameselle-Teijeiro, Jorge F Martins, Diana Schmitt, Fernando BMC Cancer Research Article BACKGROUND: PPP2R2A deletions were recently linked to a subgroup of luminal breast carcinoma (BC) that exhibits poor survival. This subgroup also exhibited amplification of a chromosome region containing the Cyclin D1 coding gene, CCND1. Therefore, we aimed to investigate whether a combination of PPP2R2A (B55α) and Cyclin D1 expression statuses evaluated by immunohistochemistry (IHC) could define a subgroup of luminal BC that exhibits poor survival. METHODS: First we conducted a retrospective cohort study using sequencing data from The Cancer Genome Atlas initiative to correlate PPP2R2A copy number alteration (CNA) status with its expression level and the corresponding overall survival (OS). Next, also using a retrospective cohort study design, we evaluated the PPP2R2A (B55α) expression levels by IHC in a total of 807 BC patients from two independent cohorts (discovery cohort n = 349 and validation cohort n = 458). Cyclin D1 expression was also evaluated, and the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype was evaluated as a predictor of disease-free survival (DFS) and OS in luminal-like BC patients. RESULTS: Deletions in the PPP2R2A gene strongly correlate with lower mRNA expression and poorer OS. PPP2R2A (B55α)(-/low) carcinomas have significantly shorter DFS and OS. Furthermore, in univariate analysis, the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype is significantly associated with poorer DFS and OS. In a multivariate analysis, the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype is significantly associated with poor DFS, thus defining a group of luminal-like BC with higher risk of relapse. CONCLUSION: We demonstrate that BCs harboring PPP2R2A deletions are associated with worse OS. Moreover, this is the first study to demonstrate that the combination of altered PPP2R2A (B55α) and high Cyclin D1 expression by IHC defines a subgroup of luminal-like BC patients with a high risk of relapse and death. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1266-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-15 /pmc/articles/PMC4409761/ /pubmed/25879784 http://dx.doi.org/10.1186/s12885-015-1266-1 Text en © Beca et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Beca, Francisco
Pereira, Miguel
Cameselle-Teijeiro, Jorge F
Martins, Diana
Schmitt, Fernando
Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer
title Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer
title_full Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer
title_fullStr Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer
title_full_unstemmed Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer
title_short Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer
title_sort altered ppp2r2a and cyclin d1 expression defines a subgroup of aggressive luminal-like breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409761/
https://www.ncbi.nlm.nih.gov/pubmed/25879784
http://dx.doi.org/10.1186/s12885-015-1266-1
work_keys_str_mv AT becafrancisco alteredppp2r2aandcyclind1expressiondefinesasubgroupofaggressiveluminallikebreastcancer
AT pereiramiguel alteredppp2r2aandcyclind1expressiondefinesasubgroupofaggressiveluminallikebreastcancer
AT cameselleteijeirojorgef alteredppp2r2aandcyclind1expressiondefinesasubgroupofaggressiveluminallikebreastcancer
AT martinsdiana alteredppp2r2aandcyclind1expressiondefinesasubgroupofaggressiveluminallikebreastcancer
AT schmittfernando alteredppp2r2aandcyclind1expressiondefinesasubgroupofaggressiveluminallikebreastcancer